Biocomposites debuted SYNICEM hip, knee and shoulder preformed spacers in Canada. The antibiotic-loaded preformed spacers are designed to preserve articular space, limb length, and joint stability during two-stage revision procedures, while aiding in the treatment of infection by bacteria sensitive to gentamicin.
Available in a range of sizes and styles for case-by-case flexibility, the SYNICEM range includes a choice of Charnley and Müller hip spacer designs, and specific left and right geometries for each knee.
SYNICEM spacers have been successfully used for more than 20 years in over 70 countries.
Michael Harris, Chief Executive Officer of Biocomposites, said: “Making SYNICEM preformed antibiotic-loaded spacers available to surgeons in Canada, less than three months after launching them in the U.S., is a source of pride for the team at Biocomposites. The quality and consistency of the SYNICEM spacer range reflects our long-standing focus on precision engineering and dependable performance, with the aim of supporting clinicians and improving care for patients with complex needs.”
Biocomposites debuted SYNICEM hip, knee and shoulder preformed spacers in Canada. The antibiotic-loaded preformed spacers are designed to preserve articular space, limb length, and joint stability during two-stage revision procedures, while aiding in the treatment of infection by bacteria sensitive to gentamicin.
Available in a range of sizes...
Biocomposites debuted SYNICEM hip, knee and shoulder preformed spacers in Canada. The antibiotic-loaded preformed spacers are designed to preserve articular space, limb length, and joint stability during two-stage revision procedures, while aiding in the treatment of infection by bacteria sensitive to gentamicin.
Available in a range of sizes and styles for case-by-case flexibility, the SYNICEM range includes a choice of Charnley and Müller hip spacer designs, and specific left and right geometries for each knee.
SYNICEM spacers have been successfully used for more than 20 years in over 70 countries.
Michael Harris, Chief Executive Officer of Biocomposites, said: “Making SYNICEM preformed antibiotic-loaded spacers available to surgeons in Canada, less than three months after launching them in the U.S., is a source of pride for the team at Biocomposites. The quality and consistency of the SYNICEM spacer range reflects our long-standing focus on precision engineering and dependable performance, with the aim of supporting clinicians and improving care for patients with complex needs.”
Copy to clipboard 
